Figure 2From: Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis No significant difference was detected between BAC and non-BAC NSCLC for three-year (A) Overall Survival (35% vs 47%, p = 0.66) and (B) Progression Free Survival (53% vs 48%, p = 0.96). Back to article page